Navigation Links
Simcere Pharmaceutical Group Reports Preliminary Unaudited Second Quarter 2011 Results
Date:8/9/2011

including Endu, Sinofuan and Jiebaishu, achieved healthy growth," said Mr. Jinsheng Ren, Chairman and Chief Executive Officer of Simcere Pharmaceutical Group. "Changes to government pricing policies have negatively impacted margins for some of our branded generic drugs, including Zailin."

Mr. Ren added, "We continue to make significant investments in R&D to support Simcere's long-term development strategy, including Bicun's overseas clinical research. In July we received approval from the SFDA to conduct clinical trials for our innovative anti-tumor drug Simotinib. Our recently announced joint-venture with Merck & Co., Inc. represents a major step forward in our strategy to cooperate with international partners to address the needs of Chinese patients."

2011 Second Quarter Financial Results Total revenue for the second quarter of 2011 was RMB546.4 million (US$84.4 million), compared to RMB544.6 million for the same period in 2010, representing a year-over-year growth of 0.3%. For the first six months of 2011, total revenue was RMB1,028.6 million (US$158.9 million), representing an increase of 2.5% from RMB1,003.2 million for the same period in 2010.

Revenue from edaravone injection productsunder the brand names Bicun and Yidasheng increased by 12.7% to RMB217.9 million (US$33.7 million) for the second quarter of 2011 from RMB193.3 million for the same period in 2010. Sales of edaravone injection products constituted 39.9% of the Company's total revenue for the second quarter of 2011. For the first six months of 2011, revenue from Bicun and Yidasheng totaled RMB406.7 million (US$62.8 million), which represented an increase of 10.9% from RMB366.7 million for the same period in 2010.

Revenue from Endu,the Company's patented anti-cancer biotech product, increased by 30.3% to RMB70.0 million (US$10.8 million) in the second quarter of 20
'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study
2. Simcere Pharmaceutical Group Announces Collaboration with OSI Pharmaceuticals
3. Simcere Pharmaceutical Group to Acquire Additional Stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd.
4. Simcere Pharmaceutical Group Announces Jiangsu Yanshens Voluntary Suspension of Production
5. Simcere Pharmaceutical Group Provides Update on Jiangsu Yanshen
6. Simcere Receives SFDA Approval to Manufacture and Sell Zanamivir in China
7. Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2009 Unaudited Financial Results on Tuesday, March 16, 2010
8. Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study
9. Simceres Diosmectite API Passes EU-GMP Inspection
10. Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results
11. Simcere Pharmaceutical Group Files Annual Report on Form 20-F
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... results for the fourth quarter of 2013 on Monday, February ... for release after the close of trading. ... conference call to discuss the operating highlights and financial results ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... 2011 Hill-Rom Holdings, Inc. (NYSE: HRC ) announced ... second quarter dividend of $0.1025 per share. This dividend is payable ... 17, 2011.   ABOUT HILL-ROM HOLDINGS, ... and provider of medical technologies and related services for the health ...
... and SYDNEY, March 7, 2011 HeartWare International, Inc. ... innovator of less invasive, miniaturized circulatory support technologies that ... announced that CEO Doug Godshall is scheduled to make ... Healthcare Conference at 8:00 a.m. Eastern Time on Tuesday, ...
Cached Medicine Technology:HeartWare to Present at the Barclays Capital 2011 Global Healthcare Conference 2
(Date:4/18/2014)... researchers have been awarded two-year grants for their work ... month. Of the 110 initial submissions to the new ... only four projects were funded, three of which are ... M.D., Ph.D.; G. William Wong, Ph.D.; and Elias Zambidis, ... oncology, will use his $500,000 proof of principle grant ...
(Date:4/18/2014)... French . ... regenerative medicine. A team led by Ludwik Leibler from ... and Didier Letourneur from the Laboratoire Recherche Vasculaire Translationnelle ... that the principle of adhesion by aqueous solutions of ... organs and tissues. This easy-to-use gluing method has been ...
(Date:4/17/2014)... Scientists have identified new pain relief targets that ... pain. BBSRC-funded researchers at King,s College London made ... nerves in the periphery of the body. , ... and identifying mechanisms underlying pain generation and our ... related side effects." , One potential side effect ...
(Date:4/17/2014)... recent papers by a University of Colorado School ... develop treatments or vaccines for Dengue fever, West ... disease-causing flaviviruses. , Jeffrey S. Kieft, PhD, associate ... School of Medicine and an early career scientist ... recently published articles in the scholarly journals ...
(Date:4/17/2014)... Doctors who treat patients with a severe and ... an agonizing treatment decision. , The drug sirolimus ... relieve shortness of breath. But some patients eventually ... potentially fatal complications following transplantation. , "It,s a ... director of Loyola University Medical Center,s LAM Clinic ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... By Amanda Gardner HealthDay Reporter , MONDAY, July ... evidence proving that staying in shape and eating right are ... that over 8 million Americans have histories of heart attack, ... the message seriously. That,s the theme of a new ...
... about clinical trials for drugs that have been approved ... health risks, an independent committee at the Institute of ... has developed a conceptual framework to guide the agency ... drug-safety trials. The recommendations of the committee, requested ...
... Parkinson disease patients aren,t walking talls ... alleviated with drugs that target dompamine, a chemical in ... and therefore known as a neurotransmitter. However, such drugs ... commonly affect individuals with severe and advanced forms of ...
... Calif., July 12, 2010 UC Irvine public health ... in impoverished reaches of China, Myanmar and Thailand, thanks ... of a seven-year, $14.5 million award to Pennsylvania State ... Diseases. Yan will collaborate with Penn State principal investigator ...
... Drinking tart cherry juice daily could help reduce the severity ... according to a new study published in the Journal ... University of Pennsylvania, University of Rochester and VA Center of ... of 15 older adults. The adults drank 8 ounces of ...
... that roams with only limited control among the rural poor ... cruzi is the triatomine insect, or "kissing bug," which thrives ... sucks the blood of mammals, helping T. cruzi ... to lie on porches or other areas easily accessible to ...
Cached Medicine News:Health News:Lifestyle Interventions Needed to Stay Heart-Healthy 2Health News:Lifestyle Interventions Needed to Stay Heart-Healthy 3Health News:Hopkins faculty lead development of report to FDA on ethical, scientific issues related to 'post-market' clinical trials 2Health News:Hopkins faculty lead development of report to FDA on ethical, scientific issues related to 'post-market' clinical trials 3Health News:JCI online early table of contents: July 12, 2010 2Health News:JCI online early table of contents: July 12, 2010 3Health News:JCI online early table of contents: July 12, 2010 4Health News:JCI online early table of contents: July 12, 2010 5Health News:JCI online early table of contents: July 12, 2010 6Health News:JCI online early table of contents: July 12, 2010 7Health News:JCI online early table of contents: July 12, 2010 8Health News:New study suggests tart cherry juice can be a natural solution for insomnia 2Health News:Dogs may help collar Chagas disease 2
... on/off switch which allows user to stop rotor ... hinge, with stainless steel pin is virtually indestructible. ... Spins 6 microcentrifuge tubes at low to medium ... g. 6 inch x 6 inch footprint. Starts ...
Inquire...
Spectrafuge 16M High speed microcentrifuge. High g-force for molecular biology applications. Brushless, maintenance-free motor. Easy to use control panel. Complete with 18 x 1.5/2.0 ml rotor. StripSp...
... Powerful single rotation speed of 10,000 ... (x g) , Pellets single- and double-stranded ... and continuous spinning , 12-position rotor holds ... 1.5-ml microcentrifuge tubes , Replaceable rotor ...
Medicine Products: